Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq
@ASCO
#ASH25#ASHPlenary#PARADIGM trial
Great work, congratulations to Dr. Fathi and colleagues! #AML#leusm
Summary:
The study met PE for EFS.
Higher ORR and CR in VEN+AZA gp
More pt received transplant in VEN+AZA gp
Better QOL